Glimepiride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1995
- First approval year
- 1995
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Glimepiride
- Molecular weight
- 490.63
- Structure (SMILES)
- CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
- amaryl
- Amaryl
- glimepiride
- Glimepiride
- glimepiride component of avandaryl
- Glimepiride component of avandaryl
- glimepiride component of duetact
- Glimepiride component of duetact
- niddaryl
- Niddaryl
- 1 p 2 3 ethyl 4 methyl 2 oxo 3 pyrroline 1 carboxamido ethyl phenyl sulfonyl 3 trans 4 methylcyclohexyl urea
- 1-((P-(2-(3-ETHYL-4-METHYL-2-OXO-3-PYRROLINE-1-CARBOXAMIDO)ETHYL)PHENYL)SULFONYL)-3-(TRANS-4-METHYLCYCLOHEXYL)UREA
- 1h pyrrole 1 carboxamide 3 ethyl 2 5 dihydro 4 methyl n 2 4 4 methylcyclohexyl amino carbonyl amino sulfonyl phenyl ethyl 2 oxo trans
- 1H-PYRROLE-1-CARBOXAMIDE, 3-ETHYL-2,5-DIHYDRO-4-METHYL-N-(2-(4-(((((4-METHYLCYCLOHEXYL)AMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-OXO-, TRANS-
- 1mg glimepiride
- 1mg Glimepiride
- 2mg Glimepiride
- 3mg Glimepiride
- 4mg Glimepiride
- Amaryl®
- AMARYL® 4 mg Tablets
- Amaryl® Tablets 1 mg
- duetact component glimepiride
- DUETACT COMPONENT GLIMEPIRIDE
- glimepirida
- Glimepirida
- glimepiride
- Glimepiride
- GLIMEPIRIDE
- Glimepiride (double-blind)
- Glimepiride (HOE490)
- GLIMEPIRIDE (HOE490)
- Glimepiride (open-label)
- Glimepiride (oral)
- Glimepiride (SU)
And 43 more, listed on the interactive page.
- ATC classification codes
- A10BB12
Sources for recorded values
- CAS registry numbers
- 93479-97-1
- ChEMBL ID
- CHEMBL1481
- InChIKey
- WIGIZIANZCJQQY-RUCARUNLSA-N
- RxNorm IDs (RxCUI)
- 25789
- FDA ingredient codes (UNII)
- 6KY687524K
- Applicant
- TAKEDA PHARMS USA
- Approval date
- 28 Jul 2006
- Application number
- NDA021925
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- glimepiride
- Type
- Synthetic organic
- Drug name stem
- gli-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
- Action type
- Blocker
- Target
- Sulfonylurea receptor 1, Kir6.2
- Protein identifier
- Q09428
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
- Action type
- Blocker
- Target
- Sulfonylurea receptor 1, Kir6.2
- Protein identifier
- Q14654
Open Targets mechanisms
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
- Action type
- Blocker
- Target
- Sulfonylurea receptor 1, Kir6.2
- Action type
- Blocker
- Gene symbol
- ABCC9|KCNJ11
- Protein identifier
- O60706|Q14654
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Blocker
- Gene symbol
- ABCC8|KCNJ11
- Protein identifier
- Q09428|Q14654
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Atherosclerosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 4
- Condition identifier
- Orphanet:552
- Subject identifier
- D003924
- Condition identifier
- EFO_0000400
- Condition identifier
- HP_0001263
- Condition identifier
- HP_0001297
- Condition identifier
- HP_0001943
- Highest recorded phase
- 3
- Condition identifier
- HP_0003074
- Condition identifier
- HP_0040270
- Condition identifier
- MONDO_0002525
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005003
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005015
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005027
- Condition identifier
- MONDO_0005068
- Condition identifier
- MONDO_0005148
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005154
- Condition identifier
- MONDO_0005240
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005300
- Condition identifier
- MONDO_0005328
- Condition identifier
- Orphanet_552
- Condition identifier
- Orphanet_552
- Highest recorded phase
- 2
- Event
- acute kidney injury
- Reports
- 142
- Reporting signal score
- 95.2582
- Event
- altered state of consciousness
- Reports
- 78
- Reporting signal score
- 133.485
- Event
- blood glucose decreased
- Reports
- 75
- Reporting signal score
- 150.768
- Event
- blood glucose increased
- Reports
- 141
- Reporting signal score
- 185.872
- Event
- blood lactic acid
- Reports
- 19
- Reporting signal score
- 96.0339
- Event
- bradypnoea
- Reports
- 19
- Reporting signal score
- 43.7235
- Event
- depressed level of consciousness
- Reports
- 57
- Reporting signal score
- 50.2525
- Event
- diabetes mellitus inadequate control
- Reports
- 133
- Reporting signal score
- 368.887
- Event
- diabetic metabolic decompensation
- Reports
- 45
- Reporting signal score
- 170.47
- Event
- drug interaction
- Reports
- 120
- Reporting signal score
- 43.8768
- Event
- glycosylated haemoglobin increased
- Reports
- 81
- Reporting signal score
- 180.75
- Event
- hyperglycaemia
- Reports
- 76
- Reporting signal score
- 101.598
- Event
- hyperhidrosis
- Reports
- 85
- Reporting signal score
- 50.3581
- Event
- hyperkalaemia
- Reports
- 72
- Reporting signal score
- 80.7592
- Event
- hypoglycaemia
- Reports
- 1,161
- Reporting signal score
- 4,365.68
- Event
- hypoglycaemic coma
- Reports
- 157
- Reporting signal score
- 658.437
- Event
- hypoglycaemic encephalopathy
- Reports
- 39
- Reporting signal score
- 194.438
- Event
- lactic acidosis
- Reports
- 132
- Reporting signal score
- 235.884
- Event
- loss of consciousness
- Reports
- 124
- Reporting signal score
- 96.8587
- Event
- neuroglycopenia
- Reports
- 11
- Reporting signal score
- 57.5223
- Event
- oliguria
- Reports
- 25
- Reporting signal score
- 45.0757
- Event
- pancreatitis acute
- Reports
- 57
- Reporting signal score
- 68.3645
- Event
- postprandial hypoglycaemia
- Reports
- 10
- Reporting signal score
- 48.4708
- Event
- renal failure acute
- Reports
- 75
- Reporting signal score
- 58.0238
- Event
- renal impairment
- Reports
- 106
- Reporting signal score
- 97.004
And 1 more, listed on the interactive page.
- NCT00000620
- NCT00032487
- NCT00044447
- NCT00099944
- NCT00106340
- NCT00131664
- NCT00151697
- NCT00294723
- NCT00309608
- NCT00318422
- NCT00318461
- NCT00318656
- NCT00331851
- NCT00343980
- NCT00347100
- NCT00353691
- NCT00359762
- NCT00360698
- NCT00427154
- NCT00437554
- NCT00449605
- NCT00469092
- NCT00469586
- NCT00474838
- NCT00562172
And 130 more, listed on the interactive page.
- Dose
- 1-2mg, up to 8mg
- Route
- Oral
- How often
- Once daily
- Administer with breakfast or first meal of the day
- Dose increases no more frequently than every 1 to 2 weeks
- Use conservative titration in at-risk patients (elderly, renal impairment)
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 124.68
- Calculated partition coefficient (ALogP)
- 3.07
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 34
- Molecular formula
- C24H34N4O5S
- Natural product
- Yes
- 0615-8332
- 0615-8333
- 0615-8334
- 16571-773
- 16571-774
- 16571-775
- 16729-001
- 16729-002
- 16729-003
- 42571-100
- 42571-101
- 42571-102
- 42571-103
- 42571-104
- 42571-105
- 43063-121
- 43063-122
- 43063-587
- 43063-630
- 43063-697
- 43063-698
- 43063-699
- 43063-946
- 43547-394
- 43547-395
And 82 more, listed on the interactive page.
Oral bioavailability
- Median
- 100
- Mean
- 100
- Minimum
- 100
- Maximum
- 100
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (363)
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
- A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes
- A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab
- A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
- A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
- A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children
- A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
- A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
- A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
- A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
- A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein
Approved for (3)
- Diabetes mellitus
- Maturity-onset diabetes of the young
- Type 2 diabetes mellitus
In development for (3)
- Atherosclerosis Phase 3
- Coronary artery disorder Phase 3
- Hypertensive disorder Phase 3